Literature DB >> 16430666

Collection of hyperconcentrated platelets with Trima Accel.

J Ringwald1, T Duerler, O Frankow, R Zimmermann, J Zingsem, E Strasser, M Antoon, R Eckstein.   

Abstract

BACKGROUND AND OBJECTIVES: Lowering the plasma content in single-donor platelet (PLT) concentrates well below 30% implies the need to collect platelets at very high concentrations. Trima Accel (TA) is validated for collection below 4000 x 10(3) PLTs/microl. We evaluated its performance at 5000 x 10(3) PLTs/microl.
MATERIALS AND METHODS: Twenty blood donors underwent apheresis with TA twice collecting either a hyperconcentrated or a standard single-donor platelet concentrate with a target platelet concentration of 5000 or 1200 x 10(3) PLTs/microl, respectively. We analysed the collection efficiency, the collection rate and the quality of the collected by-plasma.
RESULTS: We collected 20 hyperconcentrated and 20 standard units containing 2.56 +/- 0.5 and 3.39 +/- 0.4 x 10(11) PLTs at a concentration of 4518 +/- 978 and 1374 +/- 166 x 10(3) PLTs/microl in 45 +/- 8 and 39 +/- 6 min resulting in a collection efficiency of 47.5 +/- 10.0 and 70.7 +/- 7.9% and a collection rate of 5.9 +/- 1.4 and 8.8 +/- 1.5 x 10(9) PLTs/min, respectively (all results expressed as mean +/- standard deviation). The collected by-plasma showed a very high grade of cell purity and a satisfactory recovery of the clotting factors.
CONCLUSION: Although TA is a suitable device for PLT collection at very high concentrations, improvements are desirable to further increase the productivity above its currently validated upper collect concentration limit.

Entities:  

Mesh:

Year:  2006        PMID: 16430666     DOI: 10.1111/j.1423-0410.2005.00721.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  1 in total

1.  Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS).

Authors:  Sherrill J Slichter; Jill Corson; Mary Kay Jones; Todd Christoffel; Esther Pellham; S Lawrence Bailey; Doug Bolgiano
Journal:  Blood       Date:  2013-11-20       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.